Literature DB >> 16204273

Infliximab and nephrotic syndrome.

George Chin1, Grant Luxton, Jennet M Harvey.   

Abstract

Infliximab is a chimeric tumor necrosis factor-alpha (TNF-alpha) monoclonal antibody, which has been used extensively in patients with rheumatoid arthritis and inflammatory bowel disease. It also appears to be effective in other conditions such as psoriasis and ankylosing spondylitis. The major side effect of infliximab is infection. Renal complications are uncommon and not well recognized. This report describes a probable case of infliximab-induced membranous nephropathy.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16204273     DOI： 10.1093/ndt/gfi180

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN： 0931-0509            Impact factor:   5.992


  12 in total

1.  Long-term remission of nephrotic syndrome with etanercept for concomitant juvenile idiopathic arthritis.

Authors:  Shuichi Ito; Akiko Tsutsumi; Tomonori Harada; Aya Inaba; Shuichiro Fujinaga; Koichi Kamei
Journal:  Pediatr Nephrol       Date:  2010-06-09       Impact factor: 3.714

2.  Anti-tumour necrosis factor alpha therapy in patients with impaired renal function.

Authors:  Axel J Hueber; Andac Tunc; Georg Schett; Bernhard Manger
Journal:  Ann Rheum Dis       Date:  2007-03-02       Impact factor: 19.103

Review 3.  Pathogenesis of childhood idiopathic nephrotic syndrome: a paradigm shift from T-cells to podocytes.

Authors:  Kazunari Kaneko; Shoji Tsuji; Takahisa Kimata; Tetsuya Kitao; Sohsaku Yamanouchi; Shogo Kato
Journal:  World J Pediatr       Date:  2015-01-28       Impact factor: 2.764

4.  A case report on nephrotic syndrome associated with ankylosing spondylitis effectively treated with infliximab.

Authors:  Xin Feng; Yao Li; Wei Gao
Journal:  Int J Clin Exp Med       Date:  2014-09-15

Review 5.  A case report of a psoriatic arthritis patient on hemodialysis treated with tumor necrosis factor blocking agent and a literature review.

Authors:  Ioanna Saougou; Charalampos Papagoras; Theodora E Markatseli; Paraskevi V Voulgari; Alexandros A Drosos
Journal:  Clin Rheumatol       Date:  2010-05-21       Impact factor: 2.980

Review 6.  Off the beaten renin-angiotensin-aldosterone system pathway: new perspectives on antiproteinuric therapy.

Authors:  Judit Gordon; Jeffrey B Kopp
Journal:  Adv Chronic Kidney Dis       Date:  2011-07       Impact factor: 3.620

Review 7.  Kidney disease and psoriasis: novel evidences beyond old concepts.

Authors:  Luca Visconti; Giuseppe Leonardi; Michele Buemi; Domenico Santoro; Valeria Cernaro; Carlo Alberto Ricciardi; Antonio Lacquaniti; Giuseppe Coppolino
Journal:  Clin Rheumatol       Date:  2015-11-28       Impact factor: 2.980

8.  Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group.

Authors:  Melanie S Joy; Debbie S Gipson; Leslie Powell; Jacqueline MacHardy; J Charles Jennette; Suzanne Vento; Cynthia Pan; Virginia Savin; Allison Eddy; Agnes B Fogo; Jeffrey B Kopp; Daniel Cattran; Howard Trachtman
Journal:  Am J Kidney Dis       Date:  2009-11-22       Impact factor: 8.860

9.  A case of AA amyloidosis associated with rheumatoid arthritis effectively treated with Infliximab.

Authors:  Takeshi Kuroda; Yasuhiro Otaki; Hiroe Sato; Takeo Fujimura; Takeshi Nakatsue; Syuichi Murakami; Minoru Sakatsume; Masaaki Nakano; Fumitake Gejyo
Journal:  Rheumatol Int       Date:  2008-05-22       Impact factor: 2.631

10.  Minimal-change disease secondary to etanercept.

Authors:  Mariko Koya; Raimund Pichler; J Ashley Jefferson
Journal:  Clin Kidney J       Date:  2012-08-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.